Benzinga · Sep 11, 2026
This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
IL
NASDAQ · ILMN
Illumina, Inc.
Healthcare · Medical - Diagnostics & Research
$222.29
Up+$8.16 (+3.67%)
Updated Sep 16, 2026, 5:35 PM
SID Score
6.4/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 20.84B
- P/E ratio
- 30.27
- Dividend yield
- 0.00%
- 52-week range
- $88.00 – $231.81
- Volume
- 3.15M
- Avg. volume
- 1.79M
Price performance
ILMN price history
1M range · 20 trading sessions · Daily adjusted prices
ILMN closed at $222.29 after 20 trading sessions, up 18.06% for the selected period.
- Last close
- $222.29
- Period change
- +18.06%
- Period low
- $188.29
- Period high
- $227.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $208.95 | $226.76 | $207.895 | $222.29 | 3.15M |
| Sep 14, 2026 | $206.74 | $208.93 | $202.815 | $208.21 | 2.06M |
| Sep 11, 2026 | $201.81 | $208.39 | $200.01 | $206.45 | 2.41M |
| Sep 10, 2026 | $203.69 | $206.07 | $200.56 | $201.27 | 1.29M |
| Sep 9, 2026 | $211.625 | $212.18 | $203.6048 | $205.00 | 1.71M |
| Sep 8, 2026 | $218.65 | $219.45 | $210.15 | $211.06 | 1.82M |
| Sep 4, 2026 | $216.74 | $219.575 | $213.95 | $218.22 | 1.75M |
| Sep 3, 2026 | $213.24 | $221.76 | $210.94 | $221.66 | 1.72M |
| Sep 2, 2026 | $208.62 | $214.98 | $207.13 | $213.25 | 1.77M |
| Sep 1, 2026 | $212.36 | $213.385 | $206.82 | $207.13 | 1.5M |
| Aug 31, 2026 | $213.74 | $214.90 | $208.98 | $213.63 | 2.02M |
| Aug 28, 2026 | $224.73 | $225.095 | $214.61 | $215.59 | 1.79M |
| Aug 27, 2026 | $225.49 | $231.81 | $224.03 | $227.69 | 1.94M |
| Aug 26, 2026 | $220.78 | $227.70 | $220.00 | $224.84 | 1.71M |
| Aug 25, 2026 | $224.00 | $226.84 | $217.39 | $224.99 | 1.92M |
| Aug 24, 2026 | $215.98 | $223.97 | $212.37 | $223.22 | 2.25M |
| Aug 21, 2026 | $212.40 | $220.43 | $208.50 | $219.40 | 1.92M |
| Aug 20, 2026 | $200.302 | $220.32 | $200.302 | $213.24 | 3.28M |
| Aug 19, 2026 | $193.51 | $205.16 | $192.68 | $205.00 | 2.09M |
| Aug 18, 2026 | $192.13 | $192.83 | $187.541 | $188.29 | 1.19M |
Latest ILMN news
The latest Smart Investors Daily articles mentioning ILMN.
Stock researchCompany · Overview
ILMN research
Overview
Company profile and research snapshot.
Company profile
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $115.25
- Implied upside
- —
- Analysts
- 28
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Buy | — |
| Sep 3, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Canaccord Genuity | Hold | — |
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Aug 3, 2026 | Citigroup | Sell | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
S&P Dow Jones Indices CEO on Index Restructuring
Catherine Clay, CEO of S&P Dow Jones Indices, discusses the upcoming S&P reconstitution and rebalance, noting that the process is fully transparent and routine. She says market participants already know which names are entering and leaving the index, including Bloom Energy, Illumina and Everpure joining the S&P this month, and have ample time to adjust portfolios accordingly. She speaks with Romaine Bostick & Tyler Kendall on "The Close."
Yahoo · Sep 9, 2026
Encoded Therapeutics Raises $275 Million in Series F Financing to Advance ETX101 Through Pivotal Development and Accelerate its Precision Genetic Medicines Neurology Pipeline
SOUTH SAN FRANCISCO, Calif., September 09, 2026--Encoded Therapeutics Raises $275 Million in Series F Financing to Advance Precision Genetic Medicines Neurology Pipeline
Benzinga · Sep 9, 2026
UBS Upgrades Illumina to Buy, Raises Price Target to $260
UBS analyst Doug Schenkel upgrades Illumina (NASDAQ:ILMN) from Neutral to Buy and raises the price target from $135 to $260.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
